Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

Y. Delpech, C. Coutant, L. Hsu, E. Barranger, Takayuki Iwamoto, C. H. Barcenas, G. N. Hortobagyi, R. Rouzier, F. J. Esteva, L. Pusztai

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background:The aim of this study was to compare clinical and pathological outcomes after neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods:This analysis included 1895 patients (n=177 ILC; n=1718 IDC), with stage I-III breast cancer, who received neoadjuvant chemotherapy. Clinical and pathological response rates, the frequency of positive surgical margins and rate of breast-conserving surgery were compared.Results:There was a trend for fewer good clinical responses in ILC compared with IDC. Tumour downstaging was significantly less frequent in ILC. Positive or close surgical resection margins were more frequent in ILC, and breast-conserving surgery was less common (P

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalBritish Journal of Cancer
Volume108
Issue number2
DOIs
Publication statusPublished - Feb 2013
Externally publishedYes

    Fingerprint

Keywords

  • Breast cancer
  • Clinical response
  • Lobular carcinoma
  • Margins
  • Neoadjuvant chemotherapy
  • Pathological complete response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Delpech, Y., Coutant, C., Hsu, L., Barranger, E., Iwamoto, T., Barcenas, C. H., Hortobagyi, G. N., Rouzier, R., Esteva, F. J., & Pusztai, L. (2013). Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal of Cancer, 108(2), 285-291. https://doi.org/10.1038/bjc.2012.557